Chevaliez, Stéphane <br/><br/>
High-dose pegylated interferon-α and ribavirin in nonresponder hepatitis C patients and relationship with IL-28B genotype (SYREN trial).  [electronic resource] 

 -  Gastroenterology  Jul 2011 
 - 119-27 p.  digital 
<br/><br/> Publication Type: Clinical Trial, Phase II; Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't 
<br/><br/><label>ISSN: </label>1528-0012 
<br/><br/><label>Standard No.: </label>10.1053/j.gastro.2011.03.039  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Adult<br/>Aged<br/>Antiviral Agents--administration & dosage<br/>Chi-Square Distribution<br/>Drug Resistance, Viral--genetics<br/>Drug Therapy, Combination<br/>Female<br/>Genotype<br/>Hepacivirus--genetics<br/>Hepatitis C, Chronic--diagnosis<br/>Humans<br/>Interferon alpha-2<br/>Interferon-alpha--administration & dosage<br/>Interferons<br/>Interleukins--genetics<br/>Linear Models<br/>Logistic Models<br/>Male<br/>Middle Aged<br/>Odds Ratio<br/>Phenotype<br/>Polyethylene Glycols--administration & dosage<br/>RNA, Viral--blood<br/>Recombinant Proteins<br/>Ribavirin--administration & dosage<br/>Risk Assessment<br/>Risk Factors<br/>Time Factors<br/>Treatment Outcome<br/>Viral Load